Samsung Pharm. Co., Ltd. (001360.KS) Stock
Samsung Pharm. Co., Ltd.

Company profile
Samsung Pharm. reported revenue of 46.07 billion KRW for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 9.02 billion KRW. In Q1 2026 it reported net income of 8.77 billion KRW, against net income of 37.25 billion KRW a year earlier. Our analysis of its filings shows revenue shrinking from 51.96 billion KRW in fiscal year 2023 to 46.07 billion KRW in fiscal year 2025, 5.8% a year on average.
What stands out
- It returned to a profit in fiscal year 2025, 11.55 billion KRW, after 4 years of net losses (14.09 billion KRW in fiscal year 2024).
- Its net profit margin over the last four reported quarters was 28.7%, against a median of 4.2% for 6 listed companies of similar size in its industry.
- Revenue turned down in Q1 2026: down 20.6% from a year before, after a rise of 4.0% in fiscal year 2025.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Samsung Pharm. Co., Ltd.
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamins, antibiotics, and others. The company also provides medicines for the digestive system, medicines for liver disorders, medicines for the circulation system, cold medicines, nutritional supplements, health tonics, antophlegm agents, and others, as well as quasi-medicines, cold medicines, vitamins and energy drinks, and functional foods. The company was founded in 1929 and is headquartered in Hwaseong-si, South Korea.
Largest shareholders
- Gemvax&Kael Co.,Ltd.10.46%
- Samsung Pharm. Co., Ltd.0.04%
- Kyung-Pyo Jung0.004723 %0.00%
- Bong-kwon Park0.001856 %0.00%
Share of the company, as of September 25, 2026
Leadership
- Sung Tag Jung — CEO & Chairman, 48
- HwaYeong Park — Internal Director & VP
How much revenue does Samsung Pharm. make?
Samsung Pharm. reported 46.07 billion KRW in revenue for fiscal year 2025, up 4.0% from 44.29 billion KRW in fiscal year 2024. In Q1 2026 revenue was 9.02 billion KRW.
What companies are similar to Samsung Pharm.?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hana Pharm Co., Ltd. (293480.KS), Jeil Pharmaceutical Co.,Ltd (271980.KS), Ilyang Pharmaceutical Co.,Ltd (007570.KS), Handok Inc. (002390.KS).
Has Samsung Pharm. made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 40.28 billion KRW; FY2022, a loss of 25.09 billion KRW; FY2023, a loss of 24.81 billion KRW; FY2024, a loss of 14.09 billion KRW; FY2025, 11.55 billion KRW. It reported a net loss in 4 of these 5 years.
How does Samsung Pharm.'s profit margin compare with similar companies?
Net profit margin over the last four reported quarters: Samsung Pharm., 28.7%; Hana Pharm Co., Ltd. (293480.KS), 17.4%; Jeil Pharmaceutical Co.,Ltd (271980.KS), 1.7%; Ilyang Pharmaceutical Co.,Ltd (007570.KS), 6.2%; Handok Inc. (002390.KS), -1.7%; Ahn-Gook Pharmaceutical Co., Ltd. (001540.KQ), 6.3%; Dong Sung Bio Pharm.Co.,Ltd. (002210.KS), 2.2%.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Samsung Pharm. Co., Ltd. (001360.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/001360.KS